Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ablation of Unresectable Locally Advanced Pancreatic Cancer With Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability

NCT03614910 is registered in ClinicalTrials.gov with Holy Name Medical Center, Inc. as lead sponsor.

NCT NCT03614910
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03614910 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ablation of Unresectable Locally Advanced Pancreatic Cancer With Nanoknife Irreversible Electroporation (IRE) System: Response and Tolerability
Lead sponsor
Holy Name Medical Center, Inc.
Phase
Observational
Overall status
Completed
Start date
May 15, 2018
Completion date
May 1, 2021
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer